We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
- Authors
Kabbinavar, Fairooz F; Hambleton, Julie; Mass, Robert D; Hurwitz, Herbert I; Bergsland, Emily; Sarkar, Somnath
- Abstract
Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL). Three randomized clinical studies have evaluated bevacizumab in combination with FU/LV alone. A combined analysis of raw data from these studies was performed to better assess the efficacy of bevacizumab with FU/LV.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 16, p3706
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.00.232